You are here

Pipeline Plus

More Biologic Therapies Expected To Treat Advanced Plaque Psoriasis

Chris Fellner

Psoriasis is a T-cell–mediated autoimmune disorder that manifests as a variety of chronic inflammatory skin diseases requiring lifelong care.1,2 Activated T cells release cytokines, which signal the accelerated turnover of epidermal cells, along with the keratinocyte and vascular changes that characterize the various forms of psoriasis.35 Studies have isolated at least 36 genetic markers associated with these diseases.6 The presence of T lymphocytes, cytokines, and dendritic cells in psoriatic lesions has led to the development of several biologic treatments.79

Psoriasis affects an estimated 7.4 million U.S. residents.10 It can occur at any age but usually appears between the ages of 15 and 30 years.11,12 The most common variant, plaque psoriasis (psoriasis vulgaris), affects an estimated 80% to 90% of people with psoriasis.1315 Of those with plaque psoriasis, approximately 20% have moderate-to-severe disease.16 Plaque psoriasis is characterized by inflammatory, raised, dry plaques, which are usually covered by silvery-white scales. These lesions generally involve the scalp, face, trunk, and extensor surfaces of the forearms and shins (especially the elbows and knees).17

Other forms of psoriasis include flexural psoriasis (inverse or intertiginous psoriasis), which affects flexural body sites (skin folds) and genital areas; guttate psoriasis, which is characterized by small, drop-like lesions on the trunk, arms, and legs; generalized pustular psoriasis, which causes small pusfilled blisters; palmoplantar pustulosis, which affects the palms and the soles of the feet; and erythrodermic psoriasis, a potentially fatal disorder characterized by fiery redness and exfoliation of most of the body surface.1618

Risk factors for psoriasis include psychological stress; the use of certain medications, including lithium, beta blockers, antimalarial drugs, and non-steroidal anti-inflammatory drugs; oral steroid withdrawal; and streptococcal infection––all of which may stimulate T-cell proliferation.19,20

Individuals with any form of psoriasis are at increased risk of developing serious comorbid conditions, such as cardiovascular disease, diabetes mellitus, hypertension, inflammatory bowel disease, and lymphoma.2125 Psoriasis patients are also at risk of dyslipidemia, coronary calcification, increased C-reactive protein levels, decreased folate, and hyperhomocysteinemia.26 Approximately one-third of psoriasis patients develop joint inflammation (psoriatic arthritis).25,27

Patients with mild plaque psoriasis are usually started on topical therapies, such as vitamin D products, topical cortico steroids, tar-based preparations, dithranol, salicylic acid, and vitamin A products.28 These treatments are available as gels, foams, sprays, shampoos, lotions, ointments, soaps, and creams.29 Topical treatment is often combined with phototherapy.30,31 Patients with moderate-to-severe plaque psoriasis graduate to systemic therapy, with topical products relegated to occasional adjunctive use.32 Commonly used systemic agents include methotrexate, cyclosporine, acitretin (Soriatane, Connetics Corporation), and apremilast (Otezla, Celgene).3234 Biologic therapies are the next step if systemic agents fail to produce an adequate response.33 Established biologic treatments for adults with moderate-to-severe plaque psoriasis include adalimumab (Humira, AbbVie); etanercept (Enbrel, Amgen); infliximab (Remicade, Janssen); secukinumab (Cosentyx, Novartis); and ustekinumab (Stelara, Janssen) (Table 1).34 Adalimumab and etanercept are the top U.S. therapies for advanced plaque psoriasis, followed by ustekinumab.34

Ixekizumab (Taltz, Eli Lilly), a humanized immunoglobulin G4 monoclonal antibody (mAb),34 received FDA approval in March 2016 as a new biologic treatment for moderate-to-severe plaque psoriasis.35 Ixekizumab neutralizes the proinflammatory interleukin (IL)-17A cytokine.34 By targeting IL-17A, it may also inhibit another proinflammatory cytokine, tumor necrosis factor alpha (TNFα).35,36 Analysts expect ixekizumab to be used as second- or third-line therapy after TNF failure, competing with secukinumab, another IL-17 inhibitor.34

The approval of ixekizumab was closely followed by regulatory clearance of infliximab-dyyb (Celltrion/Hospira) for the treatment of adults with chronic severe plaque psoriasis. Infliximab-dyyb is biosimilar to, but not interchangeable with, infliximab. It was the second biosimilar approved by the FDA.37

Five promising biologic agents are poised to enter the psoriasis market (Table 2). Brodalumab is under FDA review. Tofacitinib recently received a complete response letter from the agency but remains in active development. Gusel-kumab, piclidenoson, and tildrakizumab are undergoing phase 3 evaluations.

Brodalumab (AstraZeneca/Valeant), an mAb that acts as an IL-17 receptor antagonist, was developed specifically to treat adults with moderate-to-severe plaque psoriasis.34 Unlike secukinumab and ixekizumab, brodalumab does not bind to the IL-17 cytokine itself.34 Targeting the IL-17 receptor has been shown to reduce inflammation.36 In May 2015, Amgen terminated its partnership with AstraZeneca as a co-developer of brodalumab because of the drug’s increased risk of suicidal ideation and behavior.38 In January 2016, the FDA accepted a biologics license application for brodalumab for the treatment of patients with moderate-to-severe plaque psoriasis and assigned a Prescription Drug User Fee Act (PDUFA) action date of November 16, 2016.39 If approved, brodalumab is expected to become a third-line therapy for patients with moderate-to-severe plaque psoriasis after traditional biologic treatments fail.34

Guselkumab (CNTO-1959, Janssen) is an anti–IL-23 mAb with anti-inflammatory properties. It is being developed for the treatment of adults with moderate-to-severe plaque psoriasis and other forms of the disease, including pustular psoriasis, erythrodermic psoriasis, and psoriatic arthritis.34 If guselkumab wins FDA approval, it is expected to grab a large share of the psoriasis market in 2017 as the first IL-23–specific inhibitor for advanced plaque psoriasis to win FDA approval.34

Piclidenoson (CF-101, Can-Fite Biopharma) is an orally bioavailable, selective A3 adenosine receptor agonist.34 It down-regulates the nuclear factor-kappa/B signaling pathway, which in turn inhibits proinflammatory cytokines and chemokines, such as TNFα. In addition, piclidenoson affects certain cellular components of inflammation, such as autoreactive T cells.40 Can-Fite is developing piclidenoson as a potential first-line oral treatment for adults with moderate-to-severe plaque psoriasis with an anticipated U.S. launch date of 2019.34

Tildrakizumab (Merck/Sun Pharmaceuticals) is an anti–IL-23 mAb that targets the IL-23 p19 subunit (IL-23 subunit alpha). The IL-23 protein is composed of p19 and p40 subunits; ustekinumab targets p40.34 Tildrakizumab is undergoing phase 3 evaluations as a treatment for adults with moderate-to-severe chronic plaque psoriasis; these trials are expected to continue until 2019. However, analysts anticipate tildrakizumab will launch in the U.S. in 2017.34

Tofacitninb (Xeljanz, Pfizer/Takeda) is an oral Janus kinase (JAK) inhibitor41 that underwent FDA review last year as a potential treatment for adults with moderate-to-severe plaque psoriasis. In October 2015, the FDA issued a complete response letter asking for additional safety analyses, and Pfizer is working on that request.42 Tofacitinib is approved in the U.S. for the treatment of patients with moderate-to-severe rheumatoid arthritis who have had an inadequate response to or are intolerant of methotrexate.41 The drug is also in phase 3 development for the treatment of patients with ulcerative colitis, psoriatic arthritis, and idiopathic juvenile arthritis. Tofacitinib is the most-advanced JAK inhibitor targeting advanced plaque psoriasis, and analysts expect it will be a first-in-class product if it eventually wins FDA approval for that indication.34

Tables

Available Biologic Therapies for Patients With Moderate-to-Severe Plaque Psoriasis3537

Drug Name
Company
Therapeutic Class FDA Approval
Adalimumab (Humira)
AbbVie
IgG1 mAb (TNFα inhibitor) 2008
Etanercept (Enbrel)
Amgen
Dimeric fusion protein (TNFα and TNFβ inhibitor) 2004
Infliximab (Remicade)
Janssen
IgG1/κ mAb (TNFα inhibitor) 2006
Infliximab-dyyb (Inflectra)
Celltrion/Hospira
Biosimilar to infliximab 2016
Ixekinumab (Taltz)
Eli Lilly
IgG4 mAb (IL-17A inhibitor) 2016
Secukinumab (Cosentyx)
Novartis
IgG1/κ mAb (IL-17A inhibitor) 2015
Ustekinumab (Stelara)
Janssen
IgG1/κ mAb (IL-12/23 p40 subunit inhibitor) 2009

IgG = immunoglobulin G; IL = interleukin; mAb = monoclonal antibody; TNF = tumor necrosis factor.

Pipeline Biologics for the Treatment of Adults With Moderate-to-Severe Plaque Psoriasis34,38,41

Product
Developers
Therapeutic Class Targeted Indication Expected Dosing Expected Pricing Strategy FDA Status
Brodalumab
AstraZeneca/Valeant
Anti–IL-17 receptor mAb Adults with moderate-to-severe plaque psoriasis 140 mg or 210 mg SC every 2 or 4 weeks, depending on clinical response Likely similar to secukinumab because both are IL-17 inhibitors with similar dosing schedules BLA accepted in January 2016; PDUFA action date: November 16, 2016
Guselkumab (CNTO-1959)
Janssen
Anti–IL-23 mAb Adults with moderate-to-severe plaque psoriasis who are eligible for phototherapy or systemic therapy, or who have failed previous treatments 100 mg SC at weeks 0 and 4, and then every 8 weeks during maintenance regimen Likely to be priced 10% to 15% higher than adalimumab because of slightly greater efficacy In late-stage development; U.S. launch expected in 2017
Piclidenoson (CF-101)
Can-Fite Biopharma
Adenosine A3 receptor agonist Adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy 2 mg orally twice daily 40% discount to oral apremilast in order to be included in insurance formularies as first-line oral therapy In late-stage development; U.S. launch expected in 2019
Tildrakizumab
Merck/Sun Pharmaceuticals
Anti–IL-23 mAb Adults with moderate-to-severe plaque psoriasis who are eligible for photo therapy or systemic therapy 100 mg or 200 mg SC every 12 weeks Likely to be priced slightly lower than secukinumab because both are IL-23 inhibitors with similar dosing schedules and PASI scores In late-stage development; U.S. launch expected in 2016
Tofacitnib (Xeljanz)*
Pfizer/Takeda
JAK inhibitor Adults with moderate-to severe plaque psoriasis 10 mg orally twice daily (twice the RA dose) Likely similar to etanercept because their efficacy profiles are similar CRL in October 2015; FDA has requested additional safety data

*Tofacinitib is currently approved for the treatment of adults with moderate-to-severe RA who have had an inadequate response to or are intolerant of methotrexate.

BLA = biologics license application; CRL = complete response letter; IL = interleukin; JAK = Janus kinase; mAb = monoclonal antibody; PASI = Psoriasis Area and Severity Index; PDUFA = Prescription Drug User Fee Act; RA = rheumatoid arthritis; SC = subcutaneous.

Author bio: 
Chris Fellner is a medical writer and the Editor of PTCommunity.com.

References

  1. Ozawa M, Aiba S. Immunopathogenesis of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:137–144.
  2. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401–407.
  3. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002;138:657–663.
  4. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248–255.
  5. Lebwohl M. Psoriasis. Lancet 2003;361:1197–1204.
  6. Tsoi LC, Spain SL, Knight J, et al. The identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics 2012;44:1341–1348.
  7. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263–271.
  8. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496–509.
  9. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866–873.
  10. Vanderpuye-Orgle J, Zhoa Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol 2015;72:961–967.
  11. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007;25:535–546.
  12. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients’ belief and attitudes towards the disease. Br J Dermatol 1996;135:533–537.
  13. Henseler T, Christopher E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450–456.
  14. Peters BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health Syst Pharm 2000;57:645–662.
  15. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263–271.
  16. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826–850.
  17. World Health Organization. Global Report on Psoriasis 2016;Available at: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf. Accessed April 22, 2016
  18. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64;(suppl 2):ii18–ii23.
  19. Abel EA, DiCicco LM, Orenberg EK, et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986;15;(5 pt 1):1007–1022.
  20. McFadden JP, Baker BS, Powles AV, Fry L. Psoriasis and streptococci: the natural selection of psoriasis revisited. Br J Dermatol 2009;160:929–937.
  21. Dreiher J, Weitzman D, Davidovici B, et al. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008;88:561–565.
  22. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735–1741.
  23. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159:895–902.
  24. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829–835.
  25. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006;298:309–319.
  26. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Dyslipidemia and oxidative stress in mild and severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001;303:33–39.
  27. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015;27:127–133.
  28. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 28March 2013;
  29. Mitra A, Atillasoy E. Topical therapies for psoriasis. In: Soung J. Psoriasis Shanghai, China: InTech. 2012;
  30. Su Y-H, Fang J-Y. Drug delivery and formulations for topical treatment of psoriasis. Exp Opin Drug Deliv 2008;5:235–249.
  31. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc 2001;76:943–949.
  32. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012;148:95–102.
  33. Menter A, Norman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137–174.
  34. Sanyal N. Psoriasis––Global Drug Forecast and Market Analysis to 2024 New York, New York: GlobalData. April 2016;
  35. Food and Drug Administration. FDA approves new psoriasis drug Taltz. March 222016;Available at: www.fda.gov/News-Events/Newsroom/PressAnnouncements/ucm491872.htm. Accessed April 26, 2016.
  36. Yiu ZZ, Warren RB. Efficacy and safety of emerging immunotherapies in psoriasis. Immunotherapy 2015;7:119–133.
  37. Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade. April 52016;Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm. Accessed May 16, 2016.
  38. Amgen. Amgen to terminate participation in co-development and commercialization of brodalumab. May 222015;Available at: http://investors.amgen.com/phoenix.zhtml?c=61656&p=irolnewsArticle&ID=2052862. Accessed April 25, 2016.
  39. Valeant Pharmaceuticals International. Valeant announces FDA acceptance of BLA submission for brodalumab in moderate-to-severe plaque psoriasis. January 252016;Available at: http://ir.bauschhealth.com/news-releases/2016/01-25-2016-130634702. Accessed April 26, 2016.
  40. David M, Akerman L, Ziv M, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol 2012;26:361–367.
  41. Xeljanz (tofacitinib tablets) prescribing information. New York, New York: Pfizer. February 2016;Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=959. Accessed April 25, 2016.
  42. Pfizer. Pfizer receives complete response letter from FDA for oral Xeljanz (tofacitinib citrate) supplemental new drug application for moderate to severe chronic plaque psoriasis. October 142015;Available at: www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_complete_response_letter_from_fda_for_oral_xeljanz_tofacitinib_citrate_supplemental_new_drug_application_for_moderate_to_severe_chronic_plaque_psoriasis. Accessed April 25, 2016.